Blastic Mantle Cell Lymphoma Developing Concurrently in a Patient with Chronic Myelogenous Leukemia and a Review of the Literature

17Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Non-Hodgkin's lymphoma (NHL) occurring as a synchronous malignancy with chronic myelogenous leukemia (CML) is rare. To our knowledge, this is the first case reported of a patient who developed mantle cell lymphoma (MCL) after therapy with imatinib mesylate for CML. After a 3-year history of CML, the patient developed a lymphocytosis associated with diarrhea, anorexia, and weight loss. Imaging studies revealed abdominal adenopathy and extensive lymphomatous infiltration of the liver, stomach, pancreas, and kidneys. Flow cytometric and cytogenetic studies were consistent with MCL. Fluorescence in situ hybridization (FISH) of the bone marrow revealed a genetically distinct lymphoid neoplasm rather than an extramedullary blast crisis of CML. The development of lung cancer, prostate cancer, CML and MCL in this patient suggests a genetic predisposition, although other factors, including environmental exposures and therapy with imatinib mesylate could have had a contributory or synergistic role in the development of MCL. © 2004 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Rodler, E., Welborn, J., Hatcher, S., Unger, K., Larkin, E., Gumerlock, P. H., … Richman, C. (2004, April). Blastic Mantle Cell Lymphoma Developing Concurrently in a Patient with Chronic Myelogenous Leukemia and a Review of the Literature. American Journal of Hematology. https://doi.org/10.1002/ajh.20025

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free